Saturday 17 October 2026 Export PROF’s income statement to Excel — free account

Profound Medical

Profound Medical’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, up 50.7% from fiscal 2024. In the quarter to June 2026, revenue grew 12.3%, EPS grew 50.0%, free cash flow grew 17.5% and total debt rose 1.01%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

6.01 0.30 −4.75%

Follow PROF

Alert me

Market cap: $230.5M
P/E: 0.0×
Fwd P/E: −8.1×
Dividend yield: —
F-score: n/a
Altman Z: 7.27
Beneish M: −2.62
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 2.56%

Capital & Financial Ratios $m

Market Cap 230.50

Revenue 19.09

Net Income (32.74)

Free Cash Flow (36.10)

Net Debt (33.76)

Current Ratio 6.46

Debt/Equity 0.09

P/E ratio 0.00

Fwd P/E (8.06)

P/S ratio 11.45

P/B ratio 4.39

Past 5Y EPS Growth —

This Y EPS Growth 41.61%

Next Y EPS Growth 25.71%

Next Y revenue growth 160.76%

Next 5Y EPS Growth 63.25%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 3.98%

10-year low 10-year high

P/B against its own 10 years 58.72%

10-year low 10-year high

EV/Sales against its own 10 years 10.83%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	26	55	60	38
Receivables	7	7	7	10
Inventory	7	6	8	10
Other	—	—	—	—
	42	69	76	59

	2023	2024	2025	Q'26
Payables	1	1	2	1
ST’ Debt	2	2	—	5
Other	2	3	4	3
	6	7	6	9

Compound Annual Growth %

	10y	5y	3y
Sales	—	17.12%	34.06%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(7.36%)	8.51%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	5	2	—	—	—
’25	3	2	5	6	16
’24	1	2	3	4	11
’23	2	2	2	2	7
’22	1	2	2	1	7
’21	1	3	3	1	7
’20	1	1	2	3	7

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(11)	—	—	—
’25	(8)	(14)	(10)	(7)	(38)
’24	(5)	(6)	(7)	(6)	(23)
’23	(6)	(5)	(4)	(7)	(23)
’22	(8)	(6)	(6)	(7)	(26)
’21	(6)	(6)	(5)	(5)	(22)
’20	(7)	(2)	(4)	(7)	(21)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(11)	—	—	—
’25	(8)	(14)	(10)	(7)	(38)
’24	(5)	(6)	(7)	(6)	(23)
’23	(6)	(5)	(4)	(7)	(23)
’22	(8)	(6)	(6)	(7)	(26)
’21	(6)	(6)	(5)	(5)	(23)
’20	(7)	(2)	(4)	(8)	(21)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	(0.26)	—	—	—
’25	—	(0.52)	—	(0.27)	—
’24	(0.26)	(0.28)	—	(0.20)	—
’23	(0.32)	(0.35)	(0.26)	(0.42)	(1.35)
’22	(0.40)	(0.28)	(0.24)	(0.46)	(1.38)
’21	(0.37)	(0.35)	(0.29)	(0.49)	(1.50)
’20	(0.19)	(0.33)	(0.32)	(0.38)	(1.25)

Fiscal quarters ending in the months shown.

value withheld pending a data check

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	7.60	6.53	10.02	3.10	7.50	6.78	3.76	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	12.49	23.14	28.97	11.70	15.49	11.42	7.99
People
People	Employees	—	—	67	75	109	109	131	131	142	162
	Revenue/emp, $m	—	0.00	0.03	0.06	0.07	0.06	0.05	0.05	0.08	0.10
Income, $m
Income, $m	Revenue	—	4	2	4	7	7	7	7	11	16
	Gross margin, %	0.00	20.45	31.46	57.26	47.56	42.95	45.22	59.90	65.89	70.77
	EBT	(12)	(15)	(15)	(15)	(22)	(31)	(28)	(28)	(28)	(42)
	EBT margin, %	0.00	(387.44)	(798.22)	(361.16)	(295.41)	(445.13)	(424.82)	(395.21)	(260.47)	(262.88)
	Net income	(12)	0	0	(15)	(22)	(31)	(29)	(28)	(28)	(43)
	Depreciation	0	1	1	2	2	2	2	1	1	1
Per share, $
Per share, $	Revenue	0.00	0.64	0.19	0.38	0.42	0.34	0.32	0.34	0.43	0.53
	Earnings	(2.89)	(2.48)	(1.52)	(1.37)	(1.25)	(1.50)	(1.38)	(1.35)	(1.12)	(1.41)
	Cash flow	(2.59)	(1.94)	(1.34)	(1.36)	(1.19)	(1.09)	(1.24)	(1.07)	(0.95)	(1.26)
	Capex	0.00	0.00	0.00	(0.02)	(0.02)	(0.03)	0.00	0.00	0.00	(0.01)
	Free cash flow	(2.59)	(1.94)	(1.34)	(1.37)	(1.21)	(1.12)	(1.24)	(1.07)	(0.95)	(1.27)
	Book value	2.65	1.84	1.95	1.29	5.63	3.94	2.50	1.47	2.44	2.20
	Shares, m	4	6	10	11	17	20	21	21	25	30
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	0.00	0.00	31.43	48.68	33.44	34.45	23.39	17.42	14.78
	P/B	—	0.00	0.00	29.38	3.65	2.85	4.43	5.39	3.08	3.58
	EV/Sales	—	0.00	0.00	30.05	37.43	23.87	28.56	20.74	12.71	11.63
	EV/FCF	—	0.00	0.00	0.00	(13.29)	(7.15)	(7.23)	(6.43)	(5.65)	(4.82)
Cash, $m
Cash, $m	Operating cash flow	(11)	(12)	(13)	(15)	(21)	(22)	(26)	(23)	(23)	(38)
	Capex	(1)	0	—	0	0	(1)	—	—	—	0
	Free cash flow	(11)	(12)	(13)	(15)	(21)	(23)	(26)	(23)	(23)	(38)
Balance, $m
Balance, $m	Working capital	13	6	22	15	93	73	58	36	63	70
	Total debt	5	4	9	9	2	1	7	7	5	4
	Net debt	(10)	(5)	(14)	(6)	(82)	(66)	(39)	(19)	(50)	(55)
	Shareholders’ equity	11	11	20	14	97	81	52	31	60	66
Returns, %
Returns, %	ROA	(60.69)	(171.60)	0.00	(63.94)	(32.11)	(32.08)	(37.92)	(52.27)	(48.72)	(57.64)
	ROIC	0.00	0.00	0.00	(107.00)	(77.98)	(127.61)	(158.59)	(147.81)	(203.16)	(230.01)
	ROE	(108.45)	(135.03)	(98.84)	(89.68)	(38.71)	(34.50)	(43.23)	(68.06)	(60.70)	(67.12)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
QSI Quantum-Si Incorporated	$286.7M	— (loss-making)	— (loss-making)	−41.79% (below 0%: shrinking)	n/m	+9.75% (above 0%: growing)	50.00%	(7,450.29%)	Compare
INFU InfuSystems Holdings, Inc.	$277.2M	31.7×	21.7×	+2.59% (above 0%: growing)	+33.33% (above 0%: growing)	−66.54% (below 0%: shrinking)	57.98%	11.24%	Compare
TMCI Treace Medical Concepts, Inc.	$267.9M	— (loss-making)	— (loss-making)	−4.24% (below 0%: shrinking)	n/m	+11.74% (above 0%: growing)	78.47%	(32.96%)	Compare
CATX Perspective Therapeutics, Inc.	$267.1M	— (loss-making)	— (loss-making)	−72.07% (below 0%: shrinking)	n/m	−66.09% (below 0%: shrinking)	100.00%	(36,120.99%)	Compare
LAB Standard BioTools Inc.	$258.5M	2.9×	— (loss-making)	−7.62% (below 0%: shrinking)	n/m	+52.76% (above 0%: growing)	52.40%	(126.28%)	Compare
TLSI TriSalus Life Sciences, Inc.	$240.1M	— (loss-making)	— (loss-making)	+1.73% (above 0%: growing)	n/m	−41.29% (below 0%: shrinking)	86.78%	(86.03%)	Compare
ELMD Electromed, Inc.	$232.3M	20.0×	25.5×	+11.64% (above 0%: growing)	+57.69% (above 0%: growing)	−25.15% (below 0%: shrinking)	78.71%	19.70%	Compare
PROF Profound Medical	$230.5M	— (loss-making)	— (loss-making)	+12.30% (above 0%: growing)	n/m	+17.51% (above 0%: growing)	78.41%	(445.67%)
RXST RxSight, Inc.	$194.2M	— (loss-making)	— (loss-making)	+0.31% (above 0%: growing)	n/m	−94.39% (below 0%: shrinking)	76.72%	(40.81%)	Compare
Median of peers	$262.8M	20.0×	—	−1.96%	—	−33.22%	77.59%	(63.42%)

All 149 Medical Devices stocks →

Profound Medical (PROF) key facts

Strength: Profound Medical’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, up 50.7% from fiscal 2024.
Profound Medical (PROF) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PROF traded at $6.01, a market capitalization of $230.5 million.
Return on equity was −67.1% and debt-to-equity 0.09.
Its Altman Z-score is 7.27 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.